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Abstract 
 
In previous work, we demonstrated that C3G suppresses Ras oncogenic transformation by a 
mechanism involving inhibition of ERK phosphorylation. Here we present evidences 
indicating that this suppression mechanism is mediated, at least in part, by serine/threonine 
phosphatases of the PP2A family. Thus: (i) ectopic expression of C3G or C3GΔCat (mutant 
lacking the GEF activity) increases specific ERK-associated PP2A phosphatase activities; (ii) 
C3G and PP2A interact, as demonstrated by immunofluorescence and co-immunoprecipitation 
experiments; (iii) association between PP2A and MEK or ERK increases in C3G 
overexpressing cells; (iv) phosphorylated-inactive PP2A level decreases in C3G expressing 
clones and, most importantly, (v) okadaic acid reverts the inhibitory effect of C3G on ERK 
phosphorylation. Moreover, C3G interacts with Ksr-1, a scaffold protein of the Ras-ERK 
pathway that also associates with PP2A. The fraction of C3G involved in transformation 
suppression is restricted to the subcortical actin cytoskeleton where it interacts with actin. 
Furthermore, the association between C3G and PP2A remains stable even after cytoskeleton 
disruption with cytochalasin D, suggesting that the three proteins form a complex at this 
subcellular compartment. Finally, C3G- and C3GΔCat-mediated inhibition of ERK 
phosphorylation is reverted by incubation with cytochalasin D. We hypothesize that C3G 
triggers PP2A activation and binding to MEK and ERK at the subcortical actin cytoskeleton, 
thus favouring ERK dephosphorylation. 
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Introduction 
 
The C3G gene product is a Crk-binding protein, acting as an exchange factor for the Rap and 
R-Ras proteins [1, 2], that plays a crucial role in integrin mediated cell adhesion and migration 
[3-7]. In several models Crk-C3G complexes participate in ERK activation via Ras- and/or 
Rap1-dependent mechanisms [8-11], but in others, such as Chinese hamster ovary (CHO) cells, 
there is an inverse correlation between the presence of a CrkII-C3G functional complex and the 
ERK activity, which suggests the involvement of C3G in an ERK suppression pathway [12]. In 
this lane, our laboratory has recently shown in NIH3T3 fibroblasts that C3G suppresses 
malignant transformation induced by several oncogenes by a process that is independent of its 
exchange activity but dependent on its SH3-binding domain. The mechanism of suppression of 
HrasLys12-mediated oncogenic transformation involves inhibition of ERK/MAPK 
phosphorylation and cyclin A expression, which result in the loss of transformed cells capacity 
to growth in non-adherent conditions [13, 14]. Our data demonstrated that C3G acts at the level 
of ERK without affecting other steps in the Ras-ERK cascade, suggesting that C3G could 
operate through the activation of cellular phosphatases. In fact, the activity of ERK/MAPK 
depends on the equilibrium between the activities of the upstream kinases and protein 
phosphatases. Dephosphorylation of either the threonine or the tyrosine residue is sufficient for 
inactivation and this can be accomplished by tyrosine-specific phosphatases, serine/threonine 
phosphatases or by dual specificity (threonine/tyrosine) phosphatases [15, 16]. The protein 
phosphatase 2A (PP2A) family comprises the major serine/threonine phosphatases involved in 
signal transduction and the regulation of growth and development [17, 18]. PP2A family of 
phosphatases are heterotrimeric holoenzymes consisting of a core dimer composed of a 
scaffolding/structural (A) subunit and a catalytic (C) subunit. This dimer associates with a 
variety of regulatory (B) subunits. Thus far, four distinct families of regulatory subunits have 
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been identified: B or PR55, B´ or PR61 (also B56), B´´ or PR72, and B´´´ or PR93/PR110 [18, 
19]. 
Immunoprecipitation studies have revealed that PP2A associates with ERK and MEK [20] 
as well as with the kinase suppressor of Ras 1 (Ksr-1) [21] and Raf1 [22]. In fact, PP2A 
phosphatases participate in both positive and negative regulation of ERK/MAPK signaling 
pathway at multiple entry points [21, 23-26] depending on the cell type, its subcellular 
localization [18] and the holoenzyme composition, being the regulatory B subunits the 
responsible of the specificity [24, 27]. 
Although C3G in its inactive state shows a cytoplasmic, perinuclear location [13], 
phosphorylated-activated C3G localizes specifically to the subcortical actin cytoskeleton and 
Golgi apparatus [28], suggesting a possible function for C3G at these subcellular 
compartments. In fact, phosphorylation of C3G results in an increase in C3G catalytic activity 
towards its substrate Rap1, which localizes mainly to the Golgi and lysosomal vesicles [29]. 
Nevertheless, the location of the Rap1-independent C3G suppressor activity has not been 
established.  
Here we show a novel function of C3G as phosphatase activator. Furthermore, the inhibitory 
effect of C3G on ERK phosphorylation seems to be mediated by phospho-ERK specific PP2A 
phosphatases. In addition, the C3G suppression function is located at the subcortical actin 
cytoskeleton, where C3G and PP2A interact. We propose that C3G suppressor activity of Ras-
mediated transformation is located at the subcortical actin cytoskeleton and involves the 
inactivation of the Ras-ERK pathway at the level of ERK by specific PP2A holoenzymes. 
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Materials and methods 
 
Cell Cultures 
In this work we used mass cultures of NIH3T3 cells stably transfected with pLTR2, 
pLTR2C3G (containing the complete human C3G cDNA) or pLTR2C3GΔCat (a C3G mutant 
devoid of its catalytic domain but retaining the transformation suppression function) alone or in 
combination with pMEXneoHrasLys12 [13, 14]. For simplification, we will refer to these 
constructs in the text as pLTR2, C3G, C3GΔCat and HrasLys12, respectively. 
 
Antibodies and organelle markers 
For immunoblotting and immunoprecipitation studies we used: anti-C3G (C-19), anti-C3G (H-
300), anti-Actin (C-11), anti-MEK1 (C-18), anti-ERK1 (K-23) and anti-Ksr-1 (C-19) from 
Santa Cruz Biotechnologies (Santa Cruz, CA, USA); anti-phospho-p44/42 MAP Kinase 
(Thr202/Tyr204) (anti-phospho-ERK1/2) and anti-phospho-MEK1/2 (Ser217/221) from Cell 
Signaling Technology, Inc. (Beverly, MA, USA); anti-PP2A, C subunit, clone 1D6 from 
Millipore-Upstate (Billerica, MA); anti-phospho-PP2A (Y307) from Epitomics, Inc. 
(Burlingame, CA, USA).  
For immunofluorescence studies we used as primary antibodies: anti-PP2A, C subunit, 
clone 1D6 and anti-C3G 1008 [13]. As secondary antibodies we used: Cy3 anti-rabbit, FITC 
anti-mouse and Cy3 anti-mouse from Jackson ImmunoResearch Laboratories, Inc. (West 
Grove, PA, USA). For detection of cytoplasmic organelles we used: Oregon Green® 514 
phalloidin from Invitrogen-Molecular Probes (Carlsbad, CA, USA) and anti-GM130 from BD 
Biosciences (San Jose, CA, USA). 
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Immunoblotting 
Whole cell lysates were prepared by extracting with Cell Lysis Buffer purchased from Cell 
Signaling Technology, Inc. (#9803) or with RIPA buffer (20 mM Tris-HCl pH 7.5, 150 mM 
NaCl, 1% Triton X-100 (or NP-40), 0.1% Na deoxycholate, 0.1% SDS) supplemented with 1 
mM PMSF, 10 µg/ml Aprotinin and 10 µg/ml Leupeptin. The cell debris was removed by 
spinning at 10,000 g for 10 min at 4 °C.  
 
Immunoprecipitation 
Immunoprecipitation was performed essentially as described [30]. Briefly, 500 µg of protein 
from whole cell lysates were incubated with the antibody for 2 h. After this, GammaBind G 
Sepharose beads (Amersham Biosciences, Uppsala, Sweden) were added, and the incubation 
was continued for one more hour. The beads with the immunocomplexes were pelleted and 
washed with 1x Cell Lysis Buffer (see above) three times and either boiled with 1x sample 
buffer for immunoblotting or processed for kinase assay.  
 
Immunofluorescence 
Culture plates (60 mm) containing 2-3 coverslips were covered with 1 µg/ml poly-lysine 
(Sigma-Aldrich, Corp. St. Louis, MO, USA) during 15 min, water washed, dried under hood 
for 2 h and seeded with 30,000 cells/plate. After overnight growth and treatment with agonists 
and inhibitors, cells were washed twice with cold PBS and fixed with freshly prepared 3.7% 
formaldehyde during 15 min, washed again three more times in PBS and permeated with 0.1% 
Triton in PBS for additional 10 min. After blocking in 1% BSA/PBS during 15 min cells were 
incubated with primary antibody, diluted in same blocking solution, for 1h followed by 
incubation in the dark with fluorescent fluorochrome-labelled specific secondary antibody. 
Finally, after three washes in PBS, coverslips were mounted over the slides with Mowiol 4-40 
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(Calbiochem, EMD Biosciences, San Diego, CA, USA) or, in the case of organelle staining, 
incubated with the specific marker and then mounted. Fluorescent images were taken with 
confocal microscope Zeiss LSM510 using software LSM510 2.8. Cy3 is excited with 2He/10Ne 
laser (emission 543 and 633 nm). FITC and Oregon Green® 514 phalloidin are excited with 
18Ar laser (emission 458, 488 or 514.5 nm). 
 
MEK assay 
Phospho-MEK1/2 proteins were immunoprecipitated from total protein extracts with anti-
phospho-MEK1/2 antibodies and suspended in a final volumen of 20 µl of kinase buffer (25 
mM Tris-HCl pH 7.5, 10 mM MgCl2, 1 mM dithiothreitol, 2 µg/ml protease inhibitors 
[soybean trypsin inhibitor, leupeptin, aprotinin], 1 mM phenylmethylsulfonyl fluoride, and 200 
µM cold ATP). Kinase reaction was performed at 30ºC for 30 min using inactive ERK2 (2µg 
per reaction) as substrate (Cell Signalling Technology, Inc.). The reaction was stopped by 
adding 8 µl of 3x sample buffer and boiled for 5 min. Samples were resolved by SDS-PAGE, 
transferred to a polyvinylidene difluoride membrane, and developed with antibodies anti-
phospho-ERK1/2. 
 
Phosphatase activity 
For the measurement of phosphatase activities associated to ERK proteins, cell lysates were 
immunoprecipitated for 2h with anti-phospho-ERK1/2 antibodies, followed by incubation with 
GammaBind G Sepharose beads for further 1 hour at 4ºC. After 2 washes in RIPA buffer and 1 
wash in RIPA buffer supplemented with 50 mM imidazol pH 7.5 and 5 mM DTT, beads were 
suspended in 180 µl of RIPA-imidazol-DTT buffer and the phosphatase reaction was carried out 
on 96 well plates coated with fresh diluted phosphatase substrate p-NPP (para-nitrophenyl 
phosphate, Sigma-Aldrich, Corp.) at a concentration of 20 mM (prepared from a 100 mM stock 
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suspended in 10 mM glycine, 1mM MgCl2, 1 mM ZnCl2). Reaction was left for 15 min at RT and 
stopped by addition of 1M NaOH. The hydrolized p-NPP generates a yellow compound that was 
measured at 405 nm in a Microplate reader Benchmark (Bio-Rad Laboratories, Hercules, CA, 
USA).  
To measure total phosphatase activity, total protein extracts were suspended in same RIPA-
imidazol-DTT buffer and added over the p-NPP-containing well. 
 
PP2A activity 
PP2A activity was determined with the “PP2A Immunoprecipitation Phosphatase Assay Kit” 
by Millipore (Billerica, MA), following the manufacturer´s recommendations. This assay is 
based on the immunoprecipitation of PP2A with specific antibodies (anti-PP2A, C subunit, 
clone 1D6), incubation with a threonine phosphopeptide (K-R-pT-I-R-R), and assessment of 
the free phosphate with malachite green which generates a compound that absorbs at 655 nm 
[31].  
 
Transient transfections 
NIH3T3 cells were transiently transfected using FuGENE 6 Transfection Reagent (Roche Applied 
Science, Indianapolis, IN, USA) as previously described [14]. DNAs used in the transfection 
experiments included constructs pLTR2, pLTR2C3G, pLTR2C3GΔCat, pLTR2C3GSH3-b and 
pMEXneoHrasLys12 described in previous works [13, 14].  
 
 
Agonists and inhibitors 
Cells were grown in 20% FBS or starved and then stimulated with 20% FBS for 5 min. Actin 
cytoskeletal polimerization inhibitor Cytochalasin D (Sigma-Aldrich, Corp.) was used at 1 µg/ml 
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for 20 min. Okadaic acid, a specific PP2A inhibitor, was used at 2 nM for 1 h and MEK inhibitor 
PD98059 at 50 µM for 1 h prior FBS stimulation.  
 
Two-Hybrid 
 
We used MATCHMAKER Two Hybrid System 3 (Clontech Laboratories, Inc., Mountain View, 
CA), a two-hybrid yeast system based on the detection of transcriptional activation produced 
when the bait, fused to the GAL4 DNA-binding domain (DNA-BD), interacts with a library 
protein fused to the GAL4 activation domain (AD) [32]. When bait and library fusion proteins 
interact, the DNA-BD and AD are brought into proximity, thus activating the transcription of 
four reporter genes: HIS3, ADE2, MEL1 and LacZ. As bait we used a KpnI-NotI fragment, 
containing the SH3-b domain of C3G (aa 209-660), cloned into plasmid pGB3. The cDNA 
library used was from human fetal brain (Clontech, Cat. #: HY4028AH). Following the 
manufacturer´s specification, colonies were checked for their ability to grow in selection 
medium -HTLA (absence of His, Trp, Leu, Adenine) and to become blue in the presence of X-
α-Gal. DNA from the selected clones was extracted and used to transform competent, 
ampicillin-resistant GC5 cells (Gene Choice, Frederick, MD, USA; Cat no. 62-7000-12). 
Plasmids were purified and sequenced using a specific oligo from the 5´ region of the AD 
protein (TACCACTACAATGGAT). Sequences were compared with NCBI (National Center 
for Biotechnology Information) data bases for their identification.  
 
Image processing 
Quantification of band intensity was performed by Image J version 1.24 software (developed at 
the National Institutes of Health).  
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Statistical analysis. 
Data are represented as mean ± s.d. As comparisons were made between two experimental 
groups, an unpaired Student’s t-test was used. Results were considered significant when 
p<0.05. 
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Results 
 
Overexpression of C3G and C3GΔCat inhibits in vitro ERK phosphorylation without affecting 
MEK1 activation 
We have demonstrated previously that C3G overexpression does not affect Ras, Raf1 and 
MEK1 activation (estimated by the level of phospho-MEK proteins), while it decreases the 
level of ERK1/2 phosphorylation [14]. To further characterize whether C3G is affecting MEK1 
activity on ERK1/2 proteins, we performed in vitro kinase assays on phospho-MEK1 
immunoprecipitates of total cell lysates of pLTR2+HrasLys12-, C3G+HrasLys12- and 
C3GΔCat+HrasLys12- NIH3T3 stable transfectants, using inactive ERK2 as substrate. PD98059 
was used as negative control of MEK activity. Fig. 1 (panel a) shows that the level of 
phosphorylated ERK2 substrate is lower in FBS-stimulated cells overexpressing C3G and 
C3GΔCat in comparison with cells carrying empty pLTR2 vector, whereas the level of 
immunoprecipitated phospho-MEK remains unaffected (panel b). In agreement with previous 
results, total cell lysates showed the same reduction in phospho-ERK1/2 in both C3G clones 
(panel c) [14]. Control expression of MEK1, ERK1/2 and exogenous DNAs are shown in 
panels d-g. It is known that the level of phosphorylated MEK is positively correlated with the 
ability to phosphorylate and activate ERK proteins [33]. Based on that, our data showing that 
C3G does not affect MEK1 phosphorylation (and consequent activity) while affecting ERK 
phosphorylation, suggest that cellular phosphatases present in the MEK1 immunoprecipitates 
are dephosphorylating ERK proteins without affecting phospho-MEK1. This implies that C3G 
might be regulating cellular phosphatases acting specifically on phospho-ERK.  
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Ectopic expression of C3G and C3GΔCat mutant activates ERK-associated cellular 
phosphatases 
To probe whether this is the case, we first measured total phosphatase activity in cell lysates of 
NIH3T3 clones overexpressing C3G or C3GΔCat together with HrasLys12 by the p-NPP 
method. Fig. 2A shows that the overexpression of both C3G and C3GΔCat in HrasLys12-
expressing cells systematically increased cellular phosphatase activity, as compared to clones 
carrying control vector pLTR2, both in serum-starved and in FBS stimulation conditions. 
These results indicate that C3G upregulates phosphatase activities by a mechanism that is 
independent of its GEF domain, which suggests this effect could be related to its 
transformation suppressor activity.  
To further understand the mechanisms involved in this novel, undescribed, function of C3G, 
and considering its inhibitory effect on HrasLys12-induced ERK1/2 phosphorylation, we 
investigated whether C3G affects phosphatases that regulate ERK activity. It is known that 
proteins implicated in ERK regulation (MEK, phosphatases), and also substrates like 
transcription factors, form a stable complex with ERK proteins [15, 34, 35]. Therefore, to study 
the effect of C3G on ERK1/2/MAPK phosphatases, lysates of pLTR2+HrasLys12-, 
C3G+HrasLys12- or C3GΔCat+HrasLys12-expressing clones were immunoprecipitated with anti-
p-MAPK p44-p42 (T202/Y204) antibodies and the associated phosphatase activity measured 
by the p-NPP method. As illustrated in Fig. 2B, ERK-associated phosphatase activity was 
significantly higher in C3G and C3GΔCat expressing clones, as compared with pLTR2-
transfected controls. This effect was more pronounced under starvation conditions and with the 
C3GΔCat mutant. These results suggest that ERK1/2 specific phosphatases are likely 
mediators of C3G inhibitory effect on ERK phosphorylation. Notice that the fold increase in 
total phosphatases due to C3G/C3GΔCat overexpression is similar to the fold increase 
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observed in ERK immunoprecipitates, suggesting that C3G is probably acting exclusively on 
ERK-associated phosphatases. 
 
C3G upregulates PP2A activity  
It is well known that PP2A family are the most abundant cellular phosphatases acting on most 
components of growth factor signaling cascades [36]. Indeed, PP2A associates with all 
members of the Raf1-ERK1/2 pathway, including the scaffold protein Ksr-1 [20-22]. To 
investigate whether C3G specifically regulates phosphatases of the PP2A family, we measured 
PP2A activity in our C3G and HrasLys12 overexpressing clones incubated in the presence or 
absence of 2 nM okadaic acid (OA), a concentration that specifically inhibits PP2A but not PP1 
phosphatases [37], Fig. 3A shows that, indeed, both C3G and C3GΔCat upregulate PP2A 
activity and, as expected, treatment with OA inhibits C3G-mediated PP2A activation. In 
agreement with this result, C3G and C3GΔCat significantly reduced the levels of 
phosphorylated (inactive) PP2A (Fig. 3B), further indicating that both C3G and C3GΔCat 
stimulate PP2A activity. Furthermore, C3G and C3GΔCat inhibition of PP2A phosphorylation 
was reverted by OA treatment (Fig. 3C), which is in agreement with previous findings [38, 39].  
 
PP2A and C3G form a complex at the subcortical actin cytoskeleton 
To gain an insight into the possible functional relationship between C3G and PP2A, we studied 
whether these two proteins interact. Thus, we performed immunoprecipitation studies with 
anti-C3G or anti-PP2A antibodies and detected the presence of C3G and PP2A by 
immunoblotting. As shown in Fig. 4A-B, C3G and PP2A were present in both 
immunoprecipitates, indicating that these two proteins form a complex. The amount of PP2A 
that interacts with C3G is correlated with the level of expression of the C3G form. Thus, Fig. 
4B shows correlation between the amount of the C3G mutant expressed and the amount of 
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PP2A detected in the corresponding C3G immunoprecipitate. Consistently, mutant C3GΔCat, 
whose detection level with available antibodies is rather poor (Fig. 4B and 1f) displays very 
low coprecipitation with PP2A. On the contrary, mutant C3G-SH3b, containing just the SH3-
binding (SH3-b) domain (aa 209-660) of C3G interacts with the larger amount of PP2A, in 
agreement with its higher expression. This interaction between C3G and PP2A is not an 
artefact due to C3G overexpression, as it was also observed with endogenous proteins 
(pLTR2+HrasT cells), neither oncogenic Ras-dependent, as it is also clearly detectable in cells 
just carrying vector pLTR2, although, in agreement with results in Figure 4B, the interaction 
increases in cells transfected with pLTR2C3G construct (data not shown). Additionally, these 
results demonstrate that the SH3-b domain of C3G is sufficient for the association with PP2A.  
     To further corroborate these interactions we studied whether these two proteins exhibit a 
similar cellular distribution. Indeed, immunofluorescence experiments showed a colocalization 
between C3G or C3GΔCat and PP2A (Fig. 4C, CytD - panels), in agreement with the 
immunoprecipitation/immunoblotting experiments. Importantly, immunofluorescence images 
show similar signal intensity and distribution patterns of C3G and C3GΔCat. The variations in 
C3G and C3GΔCat expression observed in the immunoblots are probably due to differences in 
the recognition of both protein species by the C3G antibody used in Western blot, rather than 
to real differences in expression. This is further supported by the fact that both clones also 
show similar RNA expression levels (data not shown). 
 
PP2A mediates  C3G inhibition of ERK phosphorylation 
The above results demonstrated a functional relationship between C3G and PP2A. On the other 
hand C3G upregulates ERK-associated phosphatase activities (Fig. 2B). Moreover, the 
association between PP2A and phospho-MEK or phospho-ERK was augmented in C3G- and 
C3GΔCat-overexpressing cells (Fig. 5A). All these results suggest that PP2A could be 
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involved, at least in part, in the inhibitory effect of C3G on ERK phosphorylation. To prove 
this hypothesis we determined the levels of phospho-ERK in C3G overexpressing cells in the 
presence of 2 nM okadaic acid (OA). Fig. 5B shows that, indeed, the inhibitory effect of C3G 
on ERK phosphorylation was reverted by treatment with OA, which definitively establishes a 
link between PP2A and the C3G-mediated inhibition on ERK phosphorylation. Besides, there 
is a correlation between the decrease in phospho-ERK and the decrease of phospho (inactive)-
PP2A levels in the C3G-overexpressing cells. 
All these result suggest that C3G may be forming a complex with PP2A, ERK and MEK. It 
is known that Ksr-1 acts as a scaffold for the Ras-ERK signaling pathway interacting with the 
kinase components of this pathway like MEK and ERK [40]. PP2A is also a component of the 
Ksr-1 scaffolding complex; in fact, PP2A dephosphorylate Ksr-1 in S392, a requirement for 
Ksr-1-mediated ERK activation [21]. To investigate whether C3G is also a member of the Ksr-
1 complex, we performed immunoblotting analysis on C3G immunoprecipitates with anti-Ksr-
1 antibodies. Fig. 5C shows that, indeed, Ksr-1 interacts with C3G and C3GΔCat. The amount 
of Ksr-1 that coprecipitates correlates with the amount of PP2A found in the same 
immunoprecipitates.  
 
C3G suppressor activity maps to the subcortical actin cytoskeleton 
Recently, it has been shown that endogenous Tyr 504 phosphorylated C3G localizes to the 
subcortical actin cytoskeleton and the Golgi complex [28]. To determine whether C3G suppressor 
activity correlates with any particular subcellular location, we studied the distribution of C3G and 
C3GΔCat mutant in these organelles in cells overexpressing C3G or C3GΔCat in combination 
with HrasLys12. As shown in Fig. 6A (CytD – panels), both C3G and C3GΔCat colocalize with 
actin at the subcortical cytoskeleton. These results were further confirmed by treatment with the 
actin polymerization inhibitor cytochalasin D. Thus, in the presence of cytochalasin D the fraction 
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of C3G and C3GΔCat that interacts with actin looses their cortical distribution and accumulates in 
the same positions as depolymerised actin, further confirming the authenticity of this interaction 
(Fig. 6A, CytD + panels). Subcellular fractioning using Subcellular proteome extraction kit by 
Calbiochem showed similar cytoplasmic, membrane and cytoskeletal C3G location both in wild 
type and C3G-overexpressing cells (data not shown). Thus, the apparent staining of C3G in the 
nucleus of control pLTR2 cells is an occasional artefact of the technique probably due to the low 
level of expression of endogenous C3G in these cells. 
In contrast, C3G, but not C3GΔCat, colocalized with the Golgi complex (Fig. 6B), suggesting 
that the exchange activity is the only known C3G function associated to this organelle. This is in 
agreement with previously described Rap1 distribution in Golgi [41-43].  
To further demonstrate the C3G-actin interplay, we immunoprecipitated total cell lysates from 
permanently transfected pLTR2 + HrasLys12, C3G + HrasLys12 or C3GΔCat + HrasLys12 clones with 
anti-C3G (H-300) antibodies and analyzed the interaction by immunoblotting with anti-actin (c-
11) antibodies. Fig. 6C clearly shows an increase in the amount of actin that precipitates in the 
C3G and C3GΔCat-overexpressing clones, as compared with the clone carrying pLTR2 vector 
alone. The interaction between C3G and actin is direct, as demonstrated by two-hybrid analysis, 
and is mediated by the SH3-b domain (data not shown). 
 
C3G suppressor activity requires an integral subcortical actin cytoskeleton 
To better ascertain the correlation between C3G location at the subcortical actin cytoskeleton and 
its suppressor activity on HrasLys12 transformation, we studied the effect of cytochalasin D on C3G 
and C3GΔCat-mediated inhibition of ERK phosphorylation. Fig. 7 shows that the inhibitory effect 
of C3G and C3GΔCat on Ras-mediated ERK phosphorylation was reverted in the presence of 
cytochalasin D, suggesting that the inhibitory effect of C3G on ERK activation requires an intact 
subcortical actin cytoskeleton. Furthermore, cytochalasin D treatment did not disrupt the 
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association between C3G and PP2A (Fig. 4, CytD + panels) indicating that both proteins interact 
with actin and form a complex at the subcortical cytoskeleton.  
In summary, all these results suggest that the C3G fraction bound to actin at the subcortical 
cytoskeleton interacts with, and activates phosphatases of the PP2A family that, in turn, 
dephosphorylate ERK proteins, probably contributing to the observed inhibition of Ras-mediated 
transformation.  
 18 
Discussion 
 
In previous work, our group has demonstrated that C3G exerts a role as transformation 
suppressor over several oncogenes. Also, we described the suppression mechanism as a result 
of the inhibition of ERK phosphorylation and, consequently, reduction in cyclin A expression, 
whose final effect is the loss of the anchorage-independent growth ability of the oncogenic 
cells [13, 14]. Even though C3G reduces the number of sis (PDGF), rasLys12 and v-raf–induced 
foci, C3G overexpression appears to affect exclusively a specific downstream step in the 
cascade, the ERK phosphorylation. Therefore, the fact that C3G has no effect on MEK1 
activity suggests that C3G could be acting through the activation of cellular phosphatases. The 
present work demonstrates that this is, indeed, the case; both C3G and C3GΔCat 
overexpression increased total cellular phosphatase activities, and more specifically ERK-
associated phosphatases, which is in agreement with the proposed hypothesis. It is worth 
mentioning that, although the quantitative increases in phosphatase activities are not very high, 
results are statistically significant under different experimental conditions: FBS-stimulated 
cells in total phosphatase activity (Fig. 2A) and serum-starved cells in ERK-associated 
phosphatase activity (Fig. 2B). Besides, the standard deviations are low in all experimental 
situations supporting the significance of the results.  
Among the various phosphatases regulating ERK phosphorylation, numerous evidences 
point at members of the PP2A family as mediators of the C3G suppression function: (i) PP2A 
is activated by C3G, as visualized by malachite green assay and a reduction in the levels of 
phospho-(inactive)-PP2A; (ii) interactions PP2A-MEK1 and PP2A-ERK are augmented in 
C3G-expressing clones; (iii) PP2A coprecipitates and colocalizes with C3G; (iv) and the most 
important fact that definitively establishes a link between PP2A and the suppressor function of 
C3G: okadaic acid (at a dose that specifically inhibits PP2A) reverts the inhibitory effect of 
 19 
C3G on ERK phosphorylation. It is important to point out that PP2A is found in C3G 
immunoprecipitates in control, pLTR2-transfected cells, indicating that the C3G-PP2A 
interaction is physiological, and not an artefact related to C3G or HrasLys12 overexpression (Fig. 
4B and 5C and data not shown).  
It is known that, depending on the holoenzyme composition, PP2A can act on MEK, ERK 
or both [18, 27, 44, 45]. In our case, it seems clear that the C3G-regulated PP2A holoenzyme 
acts exclusively on phospho-ERK without affecting MEK or other steps in the cascade. This 
behaviour has recently been identified in holoenzymes containing a B´ family member as 
regulatory subunit [45].   
Our results clearly demonstrated an association between C3G and PP2A. Moreover, a C3G 
fragment just containing the SH3-binding domain (aa 209-660) is sufficient for the association 
with PP2A, in concordance with the previously described role of this domain in the 
transformation suppression effect of C3G.  
Two-hybrid experiments demonstrated that the SH3-b domain of C3G interacts with two 
member of the actin family: β-actin and γ-actin (data not shown). These results are in 
concordance with those published by Radha and coworkers showing that the subcortical actin 
cytoskeleton is one of the subcellular compartments, together with the Golgi apparatus, where 
activated C3G is located [28]. Accordingly, actin was detected in C3G-immunoprecipitates of 
both C3G and C3GΔCat-expressing clones and these interactions were also confirmed by 
immunofluorescence. The apparent lack of colocalization between C3G and actin in the 
pLTR2+HrasLys12-transfected clone is probably due to the low expression level of endogenous 
C3G in these cells, as subcellular fractioning showed equal distribution of endogenous and 
ectopic C3G in the cytoskeletal fraction (data not shown). In addition, the fact that the 
colocalization between the C3G clones and actin remains stable in cells treated with the actin 
polymerization inhibitor cytochalasin D further confirms the authenticity of these interactions 
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and suggests a functional relationship between these two proteins at this subcellular 
compartment.  
Nevertheless, only full-length C3G, but not C3GΔCat, colocalizes with Golgi. As C3GΔCat 
conserves all the potential for suppressing oncogenic transformation [13], these results indicate 
that the transformation suppression function of C3G is associated to the subcortical actin 
cytoskeleton. Indeed, treatment with cytochalasine D prevents C3G-mediated ERK inhibition, 
which suggests C3G requires an intact subcortical cytoskeleton structure to exert its 
suppression function.  
Based on these results, a very attractive theory is that C3G could perform differential, 
specific functions in these two compartments. Thus, the fraction of C3G located at the Golgi 
apparatus, where Rap1 proteins are predominantly located [41-43], would function as exchange 
factor for these GTPases, while the fraction of C3G sited at the subcortical actin cytoskeleton 
would be responsible for events related with the transformation suppression.  
Both PP2A and MEK are constitutively associated to the protein scaffold of the Ras-ERK 
pathway, Ksr-1 [46]. However, less than 5% of the Ras pathway kinases, including Raf1, MEK 
and ERK are associated with Ksr-1 even under maximal stimulation conditions [46, 47]. Also, 
in the absence of mitogenic signals, the Ksr-1 complex is inactive and sequestered in Triton-
insoluble compartments [46]. The fact that C3G increases the association between PP2A and 
MEK or ERK, together with the fact that C3G itself interacts with Ksr-1, suggest that the C3G 
fraction associated to the subcortical actin cytoskeleton might contribute to the stabilization of 
the complex and/or its recruitment to this submembranal location, which result in an increase in 
the PP2A-mediated ERK dephosphorylation.  
We propose a model where the fraction of C3G localized at the subcortical actin 
cytoskeleton interacts and activates PP2A which in turns, dephosphorylates and inactivates 
ERK. In the context of Ras-transformed cells, this results in the inhibition of cyclin A 
 21 
expression and, consequently, loss of the transformed cells ability to survive under non-
adherent conditions [13, 14]. Possibly all these molecules are part of a complex where a 
scaffold protein, like Ksr-1, integrates all the components. Additional studies are needed to 
identify the specific PP2A holoenzyme regulated by C3G that mediates its transformation 
suppression effects, as well as, to determine the mechanism by which C3G activates PP2A.   
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Figure legends 
 
Fig. 1. C3G affects ERK phosphorylation but not MEK1 activity. NIH3T3 clones 
overexpressing HrasT alone or in combination with C3G or C3GΔCat were starved for 24 h, 
pretreated, when indicated, with 50 µM PD98059 for 1h and then stimulated with 20% FBS for 
5 min. Lysates were immunoprecipitated with anti-phospho-MEK1/2 antibodies and then 
subjected to in vitro kinase reactions using inactive ERK2 protein as substrate. Phosphorylated 
ERK proteins were detected with anti-phospho-ERK antibodies (panel a), then the blot was 
stripped and incubated with anti-phospho-MEK1/2 antibodies (panel b). Phospho-ERK1/2 
(panel c), total MEK1 (panel d), total ERK1/2 (panel e), C3G/C3GΔCat (panel f) and HrasLys12 
(panel g) expressions were detected in total cell lysates with corresponding antibodies. The 
panels are representative of three independent experiments. HrasT (transforming Hras): 
HrasLys12; PD: PD98059; FBS: fetal bovine serum; b: beads incubated with total cell lysate. 
 
Fig. 2. C3G upregulates phosphatase activities (A) Graphic representing relative total 
phosphatase activity in clones overexpressing HrasT alone or in combination with C3G or 
C3GΔCat, measured as absorbance at 405 nm. Cells were serum starved for 20-22 h or starved 
and then stimulated with 20% FBS for 5 min. *p<0.05 versus pLTR2 + HrasT in 20% FBS 
stimulation condition. The histogram represents the media and s.d. of three independent 
experiments. (B) Upper: Graphic representing relative phosphatase activity associated to Thr 
202 and Tyr 204 phosphorylated ERK1/2 proteins in clones overexpressing HrasT alone or in 
combination with C3G or C3GΔCat, measured as absorbance at 405 nm. Cells were serum 
starved for 20-22 h or starved and then stimulated with 20% FBS for 5 min. *p< 0.05 versus 
pLTR2 + HrasT in starved condition. The graphic corresponds to three different experiments. 
HrasT: HrasLys12. Lower: Representative Western blot of the same lysates (20 µg) used for the 
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phosphatase assays showing similar amounts of total ERK1/2 in all samples. Numbers indicate 
the samples order. 
 
Fig. 3. C3G upregulates PP2A activity. (A) Upper: Graphic representing relative PP2A 
activity in clones overexpressing HrasLys12 alone or in combination with C3G or C3GΔCat, 
measured as absorbance at 655 nm. Subconfluent cell cultures were serum starved for 20-22 h 
and then treated with 2 nM OA for 1h, when indicated. PP2A activity was determined by the 
malachite green assay. *p<0.05, ***p<0.001 versus pLTR2 + HrasT #p<0.05 versus non-
treated C3GΔCat + HrasT; ##p<0.01 versus non-treated C3G + HrasT. The histogram 
represents the media and s.d. of six independent experiments. Lower: Representative Western 
blot of the same immunoprecipitates used for the PP2A assays showing similar amounts of 
PP2A in all samples. Numbers indicate the samples order. (B) Lysates of the indicated clones, 
growing in 20% FBS, were subjected to immunoblotting with anti-phospho-PP2A (p-PP2A) 
antibodies. After stripping, the blot was incubated with anti-PP2A antibodies. The graphic 
corresponds to two different experiments and represents the ratio phospho-PP2A/PP2A in 
relative units. *p< 0.05, **p< 0.01 versus pLTR2 + HrasT. (C) Immunoblots, with the 
indicated antibodies, of total cell lysates of same clones as in B treated or not with 2 nM OA 
(1h). HrasT: HrasLys12. The ratio p-PP2A/PP2A is indicated. 
 
Fig. 4. C3G interacts and colocalizes with PP2A. (A) Cell lysates (0.5 mg) of the indicated 
clones were immunoprecipitated with anti-PP2A antibodies and the presence of PP2A or C3G 
detected by immunoblotting. C3G and PP2A expression was also determined in the total cell 
lysates (TCL panels). (B) Cell lysates of transiently transfected NIH3T3 clones were 
immunoprecipitated with anti-C3G (H-300) antibody and the presence of PP2A or C3G 
detected by immunoblotting. The first four lanes (TCL) correspond to total cell lysates (20 µg). 
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b: beads incubated with cell lysate. (C) Inmunofluorescences of permanently transfected 
NIH3T3 clones, overexpressing HrasT alone or in combination with C3G or C3GΔCat, with 
anti-C3G 1008 and anti-PP2A antibodies, where C3G is visualized with anti-rabbit-Cy3 (upper 
panels) and PP2A with anti-mouse FITC secondary antibodies (middle panels). The 
superposition of both signals is represented in the lower panels. Cells were grown in 20% FBS 
without treatment (-) or treated (+) with 1 µg/ml of cytochalasin D (CytD) for 20 minutes. 
HrasT: HrasLys12. The scale bars represent 50 and 100 µm. 
 
Fig. 5. PP2A mediates C3G inhibitory effect on ERK phosphorylation.  (A) C3G 
upregulates PP2A interaction with MEK and ERK. Cell lysates of the indicated clones were 
immunoprecipitated with anti-phospho-ERK1/2 antibodies (p-ERK) or anti-phospho-MEK1/2 
antibodies (p-MEK) and PP2A detected by immunoblotting. PP2A, p-ERK1/2, ERK1/2, C3G 
and C3GΔCat expression were detected in total cell lysates (TCL) with corresponding 
antibodies. (B) Immunoblottings of phospho-ERK1/2 (upper panel) in cell lysates of 
pLTR2+HrasT and C3G+HrasT clones treated with okadaic acid (OA) as indicated. After 
stripping, phospho-ERK blot was incubated with anti-phospho-PP2A antibodies (middle panel) 
and, after a second stripping, with anti-ERK antibodies (lower panel). (C) Cell lysates of the 
indicated clones were immunoprecipitated with anti-C3G (H-300) antibodies and the presence 
of Ksr-1 and PP2A detected by immunoblotting with specific antibodies. Lower panels: Ksr-1 
and C3G/C3GΔCat expression in the TCL. HrasT: HrasLys12. b: beads incubated with cell 
lysate. 
 
Fig. 6. C3G interacts with actin in vivo and in vitro. (A) C3G colocalizes with actin at the 
subcortical cytoskeleton. Inmunofluorescences performed in stably transfected NIH3T3 cells 
with pLTR2+HrasT, C3G+HrasT and C3GΔCat+HrasT in which C3G is visualized by 
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incubation with antibody anti-C3G #1008 followed by incubation with Cy3, F-actin is stained 
for Oregon-Green 514 Phalloidin, and merged panels are in lower position. Cells were grown 
in 20% FBS without treatment (-) or treated (+) with 1 µg/ml of cytochalasin D for 20 minutes. 
(B) C3G, but not C3GΔCat localizes at the Golgi. Same NIH3T3 stably transfected clones 
were stained for C3G #1008 and Cy3 and the yuxtanuclear region of Golgi apparatus stained 
for GM130 (FITC). The merged images are shown in the lower panels. The scale bar represents 
100 µm. (C) Cell lysates of the same NIH3T3 stable transfectants were subjected to 
immunoprecipitation with anti-C3G (H-300) antibodies and C3G-actin complexes visualized 
by immunoblotting with anti-C3G and anti-actin (c-11) antibodies. The specificity of actin 
signal was demonstrated by stripping and reblotting with anti-actin antibodies blocked with the 
control peptide (CP). In parallel, expression levels of C3G/C3GΔCat and actin were analyzed 
by immunoblotting using 20 µg of total cell lysates (TCL) and corresponding antibodies (lower 
panels). HrasT: HrasLys12. b: beads incubated with cell lysate.  
 
Fig. 7. C3G and C3GΔCat inhibition of ERK1/2 phosphorylation requires an intact actin 
cytoskeleton. Lysates of NIH3T3 clones permanently transfected with pLTR2+HrasT, 
C3G+HrasT or C3GΔCat+HrasT were treated as indicated and the levels of phospho-ERK1/2 
(p-ERK1/2) determined by immunoblotting with specific antibodies. Blot was stripped and 
incubated with anti-ERK antibodies as loading control. CytD: cytochalasin D; HrasT: 
HrasLys12. 









